Specialization of tumour vasculature

[1]  R. Folberg,et al.  Vasculogenic mimicry , 2004, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[2]  D. Taverna,et al.  Enhanced pathological angiogenesis in mice lacking β3 integrin or β3 and β5 integrins , 2002, Nature Medicine.

[3]  L. Zardi,et al.  Lack of specificity of endoglin expression for tumor blood vessels , 2001, International journal of cancer.

[4]  R. Jain,et al.  LYVE-1 is not restricted to the lymph vessels: expression in normal liver blood sinusoids and down-regulation in human liver cancer and cirrhosis. , 2001, Cancer research.

[5]  David A. Cheresh,et al.  Apoptosis of adherent cells by recruitment of caspase-8 to unligated integrins , 2001, The Journal of cell biology.

[6]  Zhiwei Hu,et al.  Targeting tissue factor on tumor vascular endothelial cells and tumor cells for immunotherapy in mouse models of prostatic cancer , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[7]  W. Stallcup,et al.  NG2 proteoglycan is expressed exclusively by mural cells during vascular morphogenesis , 2001, Developmental dynamics : an official publication of the American Association of Anatomists.

[8]  K. Kinzler,et al.  Cell surface tumor endothelial markers are conserved in mice and humans. , 2001, Cancer research.

[9]  E C Nice,et al.  Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF‐C/D receptor VEGFR‐3 , 2001, The EMBO journal.

[10]  P. Meltzer,et al.  Cooperative interactions of laminin 5 gamma2 chain, matrix metalloproteinase-2, and membrane type-1-matrix/metalloproteinase are required for mimicry of embryonic vasculogenesis by aggressive melanoma. , 2001, Cancer research.

[11]  E. Ruoslahti,et al.  A Signaling Pathway from the α5β1 and αvβ3 Integrins That Elevatesbcl-2 Transcription* , 2001, The Journal of Biological Chemistry.

[12]  Paul S. Meltzer,et al.  Expression and functional significance of VE-cadherin in aggressive human melanoma cells: Role in vasculogenic mimicry , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[13]  D. Jackson,et al.  LYVE-1, the lymphatic system and tumor lymphangiogenesis. , 2001, Trends in immunology.

[14]  D. Spencer,et al.  A strategy for antitumor vascular therapy by targeting the vascular endothelial growth factor: receptor complex. , 2001, Cancer research.

[15]  Holger Gerhardt,et al.  Lack of Pericytes Leads to Endothelial Hyperplasia and Abnormal Vascular Morphogenesis , 2001, The Journal of cell biology.

[16]  M. Hendrix,et al.  Molecular regulation of tumor cell vasculogenic mimicry by tyrosine phosphorylation: role of epithelial cell kinase (Eck/EphA2). , 2001, Cancer research.

[17]  Y. Chen,et al.  RGD-Tachyplesin inhibits tumor growth. , 2001, Cancer research.

[18]  M. Pepper,et al.  Lymphangiogenesis and tumor metastasis: myth or reality? , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[19]  G. Yancopoulos,et al.  Ephrin-B2 selectively marks arterial vessels and neovascularization sites in the adult, with expression in both endothelial and smooth-muscle cells. , 2001, Developmental biology.

[20]  G Garcia-Cardena,et al.  Expression of ephrinB2 identifies a stable genetic difference between arterial and venous vascular smooth muscle as well as endothelial cells, and marks subsets of microvessels at sites of adult neovascularization. , 2001, Developmental biology.

[21]  L. Orci,et al.  Vascular endothelial growth factor‐C‐mediated lymphangiogenesis promotes tumour metastasis , 2001, The EMBO journal.

[22]  E Ruoslahti,et al.  Solution structures and integrin binding activities of an RGD peptide with two isomers. , 2001, Biochemistry.

[23]  Thomas Hawighorst,et al.  Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis , 2001, Nature Medicine.

[24]  Steven A. Stacker,et al.  VEGF-D promotes the metastatic spread of tumor cells via the lymphatics , 2001, Nature Medicine.

[25]  W. Arap,et al.  CD13/APN is activated by angiogenic signals and is essential for capillary tube formation. , 2001, Blood.

[26]  M. Yi,et al.  A fibronectin fragment inhibits tumor growth, angiogenesis, and metastasis. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[27]  D. Boger,et al.  Disruption of matrix metalloproteinase 2 binding to integrin alpha vbeta 3 by an organic molecule inhibits angiogenesis and tumor growth in vivo. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[28]  H. Kosmehl,et al.  Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumors in mice. , 2001, Cancer research.

[29]  E. Ruoslahti,et al.  Platelet-derived Growth Factor Receptor β and Vascular Endothelial Growth Factor Receptor 2 Bind to the β3Integrin through Its Extracellular Domain* , 2000, The Journal of Biological Chemistry.

[30]  R K Jain,et al.  Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[31]  E. Pasquale,et al.  The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization , 2000, Oncogene.

[32]  E. Ruoslahti.  Targeting tumor vasculature with homing peptides from phage display. , 2000, Seminars in cancer biology.

[33]  S. Kennel,et al.  Labeling and distribution of linear peptides identified using in vivo phage display selection for tumors. , 2000, Nuclear medicine and biology.

[34]  Fulvio Magni,et al.  Enhancement of tumor necrosis factor α antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13) , 2000, Nature Biotechnology.

[35]  S. Dallabrida,et al.  Expression of Antisense to Integrin Subunit β3Inhibits Microvascular Endothelial Cell Capillary Tube Formation in Fibrin* , 2000, The Journal of Biological Chemistry.

[36]  T. Byzova,et al.  A mechanism for modulation of cellular responses to VEGF: activation of the integrins. , 2000, Molecular cell.

[37]  P. Carmeliet,et al.  Angiogenesis in cancer and other diseases , 2000, Nature.

[38]  H. Fukuda,et al.  Anatomic distribution of intraprostatic lymphatics: Implications for the lymphatic spread of prostate cancer—A preliminary study , 2000, The Prostate.

[39]  K. Kinzler,et al.  Genes expressed in human tumor endothelium. , 2000, Science.

[40]  R. Jain,et al.  Absence of functional lymphatics within a murine sarcoma: a molecular and functional evaluation. , 2000, Cancer research.

[41]  Semi Kim,et al.  Regulation of Angiogenesis in Vivo by Ligation of Integrin α5β1 with the Central Cell-Binding Domain of Fibronectin , 2000 .

[42]  Jeffrey W. Smith,et al.  Functional activation of integrin αvβ3 in tumor cells expressing membrane‐type 1 matrix metalloproteinase , 2000 .

[43]  R K Jain,et al.  Openings between defective endothelial cells explain tumor vessel leakiness. , 2000, The American journal of pathology.

[44]  A. Pozzi,et al.  Elevated matrix metalloprotease and angiostatin levels in integrin alpha 1 knockout mice cause reduced tumor vascularization. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[45]  S. Groshen,et al.  Integrins αvβ3 and αvβ5 Are Expressed by Endothelium of High-Risk Neuroblastoma and Their Inhibition Is Associated with Increased Endogenous Ceramide , 2000 .

[46]  R. Jain,et al.  Vasculogenic mimicry: how convincing, how novel, and how significant? , 2000, The American journal of pathology.

[47]  R Folberg,et al.  Vasculogenic mimicry and tumor angiogenesis. , 2000, The American journal of pathology.

[48]  R Pasqualini,et al.  Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. , 2000, Cancer research.

[49]  T. Veikkola,et al.  Regulation of angiogenesis via vascular endothelial growth factor receptors. , 2000, Cancer research.

[50]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[51]  Candace S. Johnson,et al.  A Novel Approach for the Identification of Unique Tumor Vasculature Binding Peptides Using an E. coli Peptide Display Library , 2000, Annals of Surgical Oncology.

[52]  Napoleone Ferrara,et al.  Clinical applications of angiogenic growth factors and their inhibitors , 1999, Nature Medicine.

[53]  D. Anderson,et al.  Symmetrical mutant phenotypes of the receptor EphB4 and its specific transmembrane ligand ephrin-B2 in cardiovascular development. , 1999, Molecular cell.

[54]  P. Meltzer,et al.  Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. , 1999, The American journal of pathology.

[55]  Erkki Ruoslahti,et al.  Anti-cancer activity of targeted pro-apoptotic peptides , 1999, Nature Medicine.

[56]  G. Yancopoulos,et al.  Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. , 1999, Science.

[57]  R Pasqualini,et al.  NG2 proteoglycan-binding peptides target tumor neovasculature. , 1999, Cancer research.

[58]  K. Alitalo,et al.  VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer. , 1999, The American journal of pathology.

[59]  D. Cheresh,et al.  The role of alphav integrins during angiogenesis: insights into potential mechanisms of action and clinical development. , 1999, The Journal of clinical investigation.

[60]  R. Soldi,et al.  Role of αvβ3 integrin in the activation of vascular endothelial growth factor receptor‐2 , 1999, The EMBO journal.

[61]  E. Tschachler,et al.  Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: podoplanin as a specific marker for lymphatic endothelium. , 1999, The American journal of pathology.

[62]  R. Hynes,et al.  Extensive Vasculogenesis, Angiogenesis, and Organogenesis Precede Lethality in Mice Lacking All αv Integrins , 1998, Cell.

[63]  C. Damsky,et al.  Trophoblast pseudo-vasculogenesis: faking it with endothelial adhesion receptors. , 1998, Current opinion in cell biology.

[64]  David A. Cheresh,et al.  Detection of tumor angiogenesis in vivo by αvβ3-targeted magnetic resonance imaging , 1998, Nature Medicine.

[65]  E. Ruoslahti,et al.  Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. , 1998, Science.

[66]  R. Jain,et al.  Delivery of Molecular and Cellular Medicine to Solid Tumors , 1997, Advanced drug delivery reviews.

[67]  M. Detmar,et al.  Angiogenesis promoted by vascular endothelial growth factor: regulation through alpha1beta1 and alpha2beta1 integrins. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[68]  Donald,et al.  Angiogenesis promoted by vascular endothelial growth factor: Regulation through a 1 b 1 and a 2 b 1 integrins , 1997 .

[69]  R. Jain.  The Eugene M. Landis Award Lecture 1996. Delivery of molecular and cellular medicine to solid tumors. , 1997, Microcirculation.

[70]  F. Giancotti,et al.  The Adaptor Protein Shc Couples a Class of Integrins to the Control of Cell Cycle Progression , 1996, Cell.

[71]  D. Hanahan,et al.  Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis , 1996, Cell.

[72]  G. Hair,et al.  In situ detection of tissue factor in vascular endothelial cells: Correlation with the malignant phenotype of human breast disease , 1996, Nature Medicine.

[73]  David A. Cheresh,et al.  Definition of Two Angiogenic Pathways by Distinct αv Integrins , 1995, Science.

[74]  F. Sarkar,et al.  Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. , 1995, The Journal of clinical investigation.

[75]  A. Pandey,et al.  Role of B61, the ligand for the Eck receptor tyrosine kinase, in TNF-alpha-induced angiogenesis. , 1995, Science.

[76]  L. Zardi,et al.  The fibronectin isoform containing the ed‐b oncofetal domain: A marker of angiogenesis , 1994, International journal of cancer.

[77]  D. Cheresh,et al.  Requirement of vascular integrin alpha v beta 3 for angiogenesis. , 1994, Science.

[78]  R. Hynes,et al.  Embryonic mesodermal defects in alpha 5 integrin-deficient mice. , 1993, Development.

[79]  A. Ullrich,et al.  Up-regulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis. , 1993, Cancer research.

[80]  E. Dejana,et al.  Human endothelial cells express integrin receptors on the luminal aspect of their membrane. , 1992, Blood.

[81]  M. Schrappe,et al.  Correlation of chondroitin sulfate proteoglycan expression on proliferating brain capillary endothelial cells with the malignant phenotype of astroglial cells. , 1991, Cancer research.

[82]  R. Kerbel,et al.  Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti‐cancer therapeutic agents , 1991, BioEssays : news and reviews in molecular, cellular and developmental biology.

[83]  S Ferrone,et al.  Expression of the high molecular weight melanoma-associated antigen by pericytes during angiogenesis in tumors and in healing wounds. , 1989, The American journal of pathology.

[84]  R. Hynes,et al.  Embryonic mesodermal defects in 5 integrin-deficient mice , 1996 .